How Does Tirzepatide Work? Mechanism of Action, Per the Research

Tirzepatide is a prescription medicine, dispensed under physician supervision in the jurisdictions where regulators have authorised it. This page summarises what the published pharmacology and clinical literature report about how the molecule is understood to work. It does not describe how the medicine is used, and it contains no dosing information. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, including tirzepatide.

The Short Version: A Single Peptide Acting at Two Incretin Receptors

The incretin system refers to gut-derived hormones released after eating that amplify insulin secretion from pancreatic beta cells. Two of these hormones — GIP and GLP-1 — act at distinct G-protein-coupled receptors. Tirzepatide was engineered as a single 39-amino-acid peptide that binds both. A systematic update of the tirzepatide literature described the compound as a dual GIP and GLP-1 receptor agonist with a fatty diacid modification that supports extended circulation and once-weekly administration in trials (PMID 36498958).

A review in Cardiovascular Diabetology characterised tirzepatide as a GIP/GLP-1 receptor co-agonist developed for type 2 diabetes, and summarised glycaemic control and body-weight findings from the phase 3 programme (PMID 36050763). The dual-receptor design is the defining mechanistic feature that separates tirzepatide from single-target GLP-1 receptor agonists in the published descriptions.

Receptor Pharmacology: Imbalanced and Biased Agonism

The most detailed mechanistic characterisation in the verified literature comes from in-vitro receptor pharmacology. A 2020 study in JCI Insight reported that tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (PMID 32730231). Two separate concepts sit inside that phrase, and they are worth unpacking because they are frequently blurred together online.

"Imbalanced"

Imbalance refers to relative potency across the two receptors. The cell-based work reported that tirzepatide's activity was not evenly split between the GIP and GLP-1 receptors — it engaged one more strongly than the other rather than acting as a symmetric 50/50 co-agonist (PMID 32730231). This is laboratory receptor work, performed in engineered cell systems, not a measurement taken in people.

"Biased"

Signalling bias describes which intracellular pathway a receptor favours once activated. Class B GPCRs such as the GLP-1 receptor can couple to cyclic AMP generation via Gs proteins, and can separately recruit β-arrestin, which contributes to receptor internalisation and desensitisation. The JCI Insight study reported biased agonism at the GLP-1 receptor, with the signalling profile differing from that of the native hormone (PMID 32730231). The proposal in that literature is that reduced β-arrestin recruitment preserves receptor availability at the cell surface — but whether this specific signalling signature explains clinical differences remains a mechanistic hypothesis rather than a demonstrated causal chain in humans.

Established Mechanism vs. Proposed Mechanism

It helps to separate what the pharmacology has directly established from what is inferred.

Downstream Physiology Described in the Literature

Glucose-dependent insulin secretion

Both GIP and GLP-1 receptors are expressed on pancreatic beta cells, where activation raises intracellular cyclic AMP and amplifies insulin release in a glucose-dependent fashion — the insulin response scales with circulating glucose rather than occurring unconditionally. Reviews of the tirzepatide programme describe this incretin-driven insulinotropic action as the central glycaemic mechanism (PMID 36050763). In the phase 3 SURPASS-1 trial, researchers reported reductions in glycated haemoglobin with tirzepatide compared with placebo in participants with type 2 diabetes (PMID 34186022).

Glucagon and the alpha cell

GIP and GLP-1 have historically been described as having differing effects on glucagon secretion, and reviews of tirzepatide discuss the net effect of engaging both receptors on islet hormone balance as part of its glycaemic profile (PMID 36498958). The literature treats the relative alpha-cell contribution as an area of continued investigation rather than settled fact.

Gastric emptying and appetite signalling

GLP-1 receptor activation is associated in pharmacology literature with slowed gastric emptying and central appetite signalling via receptors in the hypothalamus and brainstem. A 2025 expert review of tirzepatide in overweight and obesity management described appetite and energy-intake pathways as central to the body-weight findings in the clinical programme (PMID 39632534). The same mechanism has a measurable pharmacokinetic consequence: a study on hormonal contraception reported that delayed gastric emptying with tirzepatide is relevant to the absorption of oral contraceptives (PMID 37940101) — a concrete example of a mechanism producing a drug-interaction consideration that belongs with a prescribing clinician.

Adipose tissue and the GIP question

The GIP receptor is also expressed on adipocytes, and the role of GIP receptor engagement in body-weight change is one of the more actively debated parts of tirzepatide pharmacology. Reviews summarising the programme noted the combined GIP/GLP-1 action alongside the magnitude of weight reduction observed across the phase 3 trials (PMID 36050763). Whether GIP receptor agonism, antagonism, or receptor desensitisation best explains adipose effects is explicitly framed as unresolved in the review literature (PMID 36498958).

Where the Mechanism Has Been Tested in Humans

Mechanism claims gain weight when the predicted physiology shows up in controlled trials. Several published trials in the verified set tested tirzepatide against active comparators:

• SURPASS-1 — a double-blind, randomised phase 3 trial that evaluated tirzepatide against placebo in participants with type 2 diabetes and reported improvements in glycaemic control (PMID 34186022).
• SURPASS-3 — a randomised, open-label phase 3 trial comparing once-weekly tirzepatide with once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors (PMID 34370970).
• SURPASS-4 — a randomised, open-label phase 3 trial comparing tirzepatide with insulin glargine in participants with type 2 diabetes and increased cardiovascular risk (PMID 34672967).
• SURPASS-5 — a randomised clinical trial of subcutaneous tirzepatide versus placebo added to titrated insulin glargine, reporting on glycaemic control (PMID 35133415).
• SURPASS-CVOT — a cardiovascular outcomes trial designed to compare tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease; the published paper described the trial design and baseline characteristics (PMID 37758044).

Beyond glycaemia, a randomised trial published in the New England Journal of Medicine investigated tirzepatide in metabolic dysfunction-associated steatohepatitis with liver fibrosis (PMID 38856224) — an extension of the mechanistic question into hepatic metabolism. Regulatory status differs by indication and by country, and approvals are decided by national regulators rather than by the literature alone.

Mechanism-Linked Adverse Events: What Studies Report

Several reported adverse events are mechanistically plausible consequences of incretin receptor activity, which is why they are discussed in the same breath as mechanism.

• Gastrointestinal events. Slowed gastric emptying and central effects on nausea pathways are the proposed basis for the gastrointestinal adverse events reported across the trials; researchers in SURPASS-1 reported gastrointestinal events as the most common adverse events with tirzepatide (PMID 34186022), and similar patterns were described in SURPASS-4 (PMID 34672967).
• Pancreatitis and gallbladder or biliary disease. A systematic review and meta-analysis specifically examined these safety signals with tirzepatide in type 2 diabetes and obesity (PMID 37908750). Biliary events are commonly linked in the literature to changes in gallbladder motility and to rapid weight change.
• Hypoglycaemia in combination settings. Because the insulinotropic action is glucose-dependent, hypoglycaemia risk in the trials was discussed primarily in the context of background insulin or sulfonylurea therapy; the SURPASS-5 trial examined tirzepatide added to titrated insulin glargine and reported on safety in that setting (PMID 35133415).

None of this constitutes a risk assessment for any individual. Safety profiles reported in trial populations do not transfer automatically to people outside those populations, and that judgement is a clinician's.

What the Mechanism Does Not Tell You

A clear mechanism is not a prediction of individual response. The receptor-level work establishes what tirzepatide does to cells in culture (PMID 32730231); the trials establish what happened on average in defined study populations under supervised conditions (PMID 34370970). Neither answers whether a given medicine is appropriate for a given person, how it interacts with other prescriptions, or what monitoring is warranted. Those are prescribing decisions. Anyone with questions about tirzepatide should direct them to a licensed physician or pharmacist who can review their full medical history.

References

• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Lancet, 2021)
• Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3) (Lancet, 2021)
• Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4) (Lancet, 2021)
• Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial (JAMA, 2022)
• Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction (Cardiovascular Diabetology, 2022)
• Tirzepatide: A Systematic Update (International Journal of Molecular Sciences, 2022)
• Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis (Frontiers in Endocrinology, 2023)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception (JAPhA, 2024)
• Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (New England Journal of Medicine, 2024)
• Tirzepatide for overweight and obesity management (Expert Opinion on Pharmacotherapy, 2025)